-
Sector Analysis
Acute-on-Chronic Liver Failure: Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Acute-on-Chronic Liver Failure Therapeutics. In 2025, there were 72,095 diagnosed incident cases of ACLF in the 16 countries covered in GlobalData’s epidemiology forecast. Acute-on-Chronic Liver Failure (ACLF) management is largely supportive and focused on complications because there is no approved therapy specifically for ACLF. Standard interventions include antimicrobials (e.g., piperacillin–tazobactam, ceftriaxone/cefotaxime, meropenem, vancomycin/linezolid), vasopressors and fluids (norepinephrine ± vasopressin), albumin/crystalloids, HBV antivirals (tenofovir or entecavir), and...
-
Sector Analysis
Emerging Market Outsourcing Report - Q3 2026
This expert outsourcing report is a comprehensive look at the pharmaceutical manufacturing landscape for emerging markets in Q3 2026, including analysis of news and trends affecting contract manufacturing organizations (CMOs) and the identification of recent contract service agreements, mergers, acquisitions, and financing among CMOs. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the pharmaceutical value chain that will provide insights into API (biologics and chemical) as well as dose manufacturing and...
-
Product Insights
Congestive Heart Failure (Heart Failure): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Congestive Heart Failure (Heart Failure) - Global Clinical Trials Review, 2026" provides an overview of Congestive Heart Failure (Heart Failure) Clinical trials scenario. This report provides top line data relating to the clinical trials on Congestive Heart Failure (Heart Failure). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Gastroesophageal (GE) Junction Carcinomas: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Gastroesophageal (GE) Junction Carcinomas - Global Clinical Trials Review, 2026" provides an overview of Gastroesophageal (GE) Junction Carcinomas Clinical trials scenario. This report provides top line data relating to the clinical trials on Gastroesophageal (GE) Junction Carcinomas . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status...
-
Product Insights
Cystic Fibrosis: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Cystic Fibrosis - Global Clinical Trials Review, 2026" provides an overview of Cystic Fibrosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Cystic Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Friedreich Ataxia: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Friedreich Ataxia - Global Clinical Trials Review, 2026" provides an overview of Friedreich Ataxia Clinical trials scenario. This report provides top line data relating to the clinical trials on Friedreich Ataxia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Bladder Cancer: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Bladder Cancer - Global Clinical Trials Review, 2026" provides an overview of Bladder Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Bladder Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Company Insights
Catalyst Monitor: Q4 2026 Outlook
This report compiles published, predictive intelligence based on interviews with key opinion leaders (KOLs) on market-moving events that are expected to occur in Q4 2026. GlobalData’s latest report, “Catalyst Monitor Q4 2026”, delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, Phase III trial results, PDUFA dates, and regulatory filings. The report covers 26 significant catalyst events that are expected to occur in Q4 2026. Some of the catalysts covered in the report, include...
-
Product Insights
Lupus Nephritis: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Lupus Nephritis - Global Clinical Trials Review, 2026" provides an overview of Lupus Nephritis Clinical trials scenario. This report provides top line data relating to the clinical trials on Lupus Nephritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
IgA Nephropathy (Berger's Disease): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “IgA Nephropathy (Berger's Disease) - Global Clinical Trials Review, 2026" provides an overview of IgA Nephropathy (Berger's Disease) Clinical trials scenario. This report provides top line data relating to the clinical trials on IgA Nephropathy (Berger's Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.